JNK3-IN-10
JNK3-IN-10 is a blood-brain barrier-impermeable JNK3 inhibitor (IC50=0.257 nM) with over 400-fold selectivity over JNK1. JNK3-IN-10 blocks the JNK3-mediated signaling pathway downstream of TGF-β1, inhibits TGF-β1-induced phosphorylation of c-Jun, reduces the expression of pro-fibrotic markers, and restores the expression of the epithelial protein E-cadherin. JNK3-IN-10 exhibits low cytotoxicity, anti-fibrotic, cytoprotective and renoprotective effects, and alleviates albuminuria, glomerulosclerosis and podocyte foot process fusion. JNK3-IN-10 can be used for the research of chronic kidney disease, glomerulosclerosis and adriamycin-induced nephropathy.
For research use only. We do not sell to patients.
- CAS No.: 3085181-00-3
- Formula: C24H24Cl2N8O2S
- Molecular Weight:559.47
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
hJNK3 0.257 nM (IC50) |
In Vitro
JNK3-IN-10 (Compound 14bg) (1 μM; pre-incubated for 20 min, co-incubated with ATP for 2 h) exhibits 84-fold, 472-fold and 194-fold selectivity over JNK1, JNK2 and p38α, respectively, and shows extremely low off-target kinase activity at the concentration of 1 μM[1].
JNK3-IN-10 (1 μM; 30 min; 37 °C) exhibits moderate microsomal stability in human liver microsomes, with 64.63% remaining after incubation at 37 °C for 30 min[1].
JNK3-IN-10 exhibits low blood-brain barrier (BBB) permeability, with a Pe value of 0.52×10-6 cm/s, and is classified as a non-BBB-permeable compound[1].
JNK3-IN-10 (5 μM; pre-incubated for 1 h) inhibits TGF-β1-induced c-Jun phosphorylation and the expression of pro-fibrotic markers (PAI-1, COL1α1) in differentiated human podocytes, without reducing cell viability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Differentiated human podocytes
-
Concentration:5 μM
-
Incubation Time:1 h pretreatment
-
Result:Suppressed TGF-β1-induced phosphorylation of c-Jun.
Showed no cytotoxicity, with cell viability remaining at control levels.
-
Cell Line:Differentiated human podocytes
-
Concentration:5 μM
-
Incubation Time:1 h pretreatment
-
Result:Attenuated TGF-β1-induced upregulation of PAI-1 and COL1α1.
Restored E-cadherin expression to near-basal levels.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male, 8 weeks old, chronic kidney disease induced by single intravenous injection of Adriamycin at 12 mg/kg)[1]
-
Dosage:2 mg/kg; 6 mg/kg
-
Administration:i.p.; three times per week; 2 weeks
-
Result:Significantly restored serum albumin levels and tended to reduce blood urea nitrogen (BUN) levels compared to untreated Adriamycin-injected mice.
Reduced urinary albumin-to-creatinine ratio, collagen-positive area, and glomerulosclerosis scores.
Decreased podocyte foot process effacement and preserved glomerular basement membrane structure.
Reduced Adriamycin-induced phosphorylation of c-Jun, suppressed upregulation of α-SMA and Col1α1, and partially restored E-cadherin expression in renal cortical tissues.
Downregulated fibrotic (α-SMA, Col1α1) and epithelial-mesenchymal transition-associated transcripts, with a trend toward recovery of podocyte-specific markers (E-cadherin, synaptopodin).
Showed no systemic toxicity.
Chemical Information
-
CAS No. 3085181-00-3
-
Molecular Weight 559.47
-
Formula C24H24Cl2N8O2S
-
SMILES
ClC1=C(C=CC(C2=C(N3C=C(SC3=N2)C(N)=O)C4=CC=NC(N[C@@H]5CCCN(C5)C(N(C)C)=O)=N4)=C1)Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)